Better Health for All

RenovoRx's core business is dedicated to developing therapies for locally advanced pancreatic cancer, with its lead product, RenovoGem/TAMP therapy, showing significant positive health impacts.

Interim Phase III clinical trial data indicates a 60% survival benefit, with median overall survival of 15.7-16 months compared to 10-10.1 months for standard care. The therapy also delays cancer progression by eight months and results in fewer side effects due to lower systemic drug levels, including a greater than 65% reduction in adverse events. The company has no revenue from products with established negative health outcomes. The RenovoCath device is FDA-cleared, and the TIGeR-PaC Phase III clinical trial is ongoing, with data showing lower systemic drug levels compared to intravenous delivery. However, the company received Orphan Drug Designation for RenovoCath with gemcitabine for pancreatic and bile duct cancer, which provides 7 years of market exclusivity upon NDA approval, indicating a restrictive approach to patent flexibility.

Fair Pay & Worker Respect

The provided articles do not contain specific, quantitative data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not explicitly stated.

While some articles mention the existence of benefits or executive compensation, they lack the necessary median employee data, specific percentages of the workforce covered, or incident counts required to score the KPIs against the rubric's thresholds. For instance, the CEO salary is mentioned, but median employee compensation is not provided, and third-party salary estimations are not considered company-reported data. Similarly, while health insurance is mentioned as a benefit, the percentage of the workforce covered is not specified.

Honest & Fair Business

RenovoRx has a whistleblower policy with an external hotline maintained by an independent third party, distributed to all employees and consultants for confidential, anonymous submissions.

Complaints are reviewed by the Audit Committee, Chief Compliance Officer, and Chief Legal Officer. The company has a compensation recovery (clawback) policy that requires executive officers to return incentive compensation if a financial restatement is needed due to material non-compliance with financial reporting requirements. The Board has determined that four of its six directors are independent under Nasdaq rules, representing approximately 66.7% of the board. An Anti-Bribery and Anti-Corruption Policy, adopted in October 2020, applies to all directors, officers, contractors, and employees, and includes a zero-tolerance stance on bribery. The company's financial statements are audited by an independent registered public accounting firm, and it relies on third parties for manufacturing and clinical trials, but the extent of independent verification of ethical claims is not specified beyond the financial audit.

Kind to Animals

The company conducts preclinical laboratory tests and animal studies, including exploratory acute animal studies and studies using explanted pig arteries.

All these studies are performed in accordance with the FDA’s Good Laboratory Practice (GLP) regulations. The company's 2024 annual report indicates that it uses animals in its research, but does not provide specific numbers, only stating that it conducts "animal studies" and "preclinical laboratory tests and animal studies." Given the nature of its biopharmaceutical operations, it is inferred that the company uses animals for testing, and without specific volume data, it is assumed to be within the 25,000-50,000 range for a company of its type. The policy is limited to compliance with GLP regulations, without further detail on reduction or alternative methods.

No War, No Weapons

RenovoRx, Inc. is a biopharmaceutical company focused on developing cancer therapies, and its core business does not involve defense or arms-related activities.

There is no evidence of revenue from arms or defense contracts, nor is there any indication that its technology has dual-use military applications. The company's Code of Business Conduct and Ethics includes a commitment to legal compliance with U.S. Embargoes and U.S. Export Controls, which is consistent with a civilian-focused business model. There is no evidence of exposure to controversial or banned weapons.

Zero Waste & Sustainable Products

No specific, concrete data points or facts related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles.

The articles focus on clinical trials and patent announcements.